Logo

Deciphera Pharmaceuticals' Qinlock (ripretinib) Receives the US FDA's Approval to Treat 4L Gastrointestinal Stromal Tumor

Share this

Deciphera Pharmaceuticals' Qinlock (ripretinib) Receives the US FDA's Approval to Treat 4L Gastrointestinal Stromal Tumor

Shots:

  • The approval is based on P-III INVICTUS study including combined safety results from the P-I study which assessing of Qinlock (150mg- qd) vs PBO in ratio (2:1) in patients with advanced GIST whose previous therapies have included imatinib- sunitinib- and regorafenib to evaluate its safety- tolerability- and efficacy
  • The study demonstrated median PFS (6.3 mos. vs 1.0 mos.)- reduced the risk of disease progression or death by 85%- mORR of 9.4%- mOS (15.1 mos. vs 6.6 mos.)- reduced the risk of death by 64%
  • Qinlock (ripretinib) is kinase inhibitor targeted to treat adult patients with advanced gastrointestinal stromal tumor (GIST)

Click here to read full press release/ article | Ref: Deciphera | Image: Deciphera


Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions